Patent ID: 6682739
Filing Date: 2004-01-27
Classification: A61K,C07K,Y10S

Abstract:
A mothod of inhibiting osteoclastogenesis comprising the step of administering to a patient an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis, wherein the inhibitor has the formula: wherein:AC is a peptide of 3-18 amino acid residues which corresponds in primary sequence to a binding loop of a TNF-R superfamily member, and which may optionally contain one or more amino acid substitutions, or an analogue thereof wherein at least one amide linkage is replaced with a substituted amide or an isostere of amide; AB1 is a moiety having a first functional group capable of forming a covalent linkage with one terminus of AC, a second functional group capable of forming a covalent linkage with AB2 and a third functional group capable of forming a covalent linkage with AA1; AB2 is a moiety having a first functional group capable of forming a covalent linkage with the second terminus of AC, a second functional group capable of forming a covalent linkage with AB1 and a third functional group capable of forming a covalent linkage with AA2; AA1 is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB2; AA2 is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB2; â€œ&boxH;â€  is a covalent linkage; and â€œâ‰¡â€  is a covalent linkage.